Trials / Completed
CompletedNCT00349180
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 156 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is performed to confirm the optimal dose for THR (total hip replacement).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin sodium |
Timeline
- Start date
- 2006-06-01
- First posted
- 2006-07-06
- Last updated
- 2009-03-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00349180. Inclusion in this directory is not an endorsement.